Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Growth in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 709,762 shares, a growth of 84.0% from the June 15th total of 385,765 shares. Currently, 5.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 507,169 shares, the short-interest ratio is presently 1.4 days.

Institutional Investors Weigh In On Lixte Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of LIXT. Axxcess Wealth Management LLC purchased a new position in Lixte Biotechnology during the fourth quarter worth about $54,000. XTX Topco Ltd purchased a new stake in shares of Lixte Biotechnology in the 4th quarter valued at approximately $57,000. Geode Capital Management LLC grew its stake in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after buying an additional 10,722 shares during the period. DRW Securities LLC increased its holdings in shares of Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after buying an additional 5,645 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Lixte Biotechnology during the 2nd quarter worth approximately $330,000. 5.10% of the stock is currently owned by institutional investors and hedge funds.

Lixte Biotechnology Stock Performance

NASDAQ LIXT opened at $7.51 on Friday. The stock’s fifty day moving average is $6.67 and its two-hundred day moving average is $4.46. The firm has a market capitalization of $112.80 million, a P/E ratio of -6.65 and a beta of 1.24. Lixte Biotechnology has a fifty-two week low of $2.02 and a fifty-two week high of $8.38.

Lixte Biotechnology (NASDAQ:LIXT) last issued its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

LIXT has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Lixte Biotechnology to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings downgraded shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.